olivLaw · US equity research
DiaMedica Therapeutics Inc. DMAC
Pharmaceutical Preparations · SIC 2834 · Vertical: Pharmaceutical Preparations (SIC 2834)
DiaMedica Therapeutics develops DM199, a recombinant form of human kallikrein-1, tested for preeclampsia, fetal growth restriction and acute ischemic stroke. The company is still in clinical stage with no approved products, and its net loss of 32.8 million USD in 2025 and cash reserve of 43.5 million USD at June 30, 2026 put funding and study results in focus now.
At the close of 04 Nov 2026, DiaMedica Therapeutics Inc. (DMAC) stock was 10.77 USD (+7.70% on the day), with market capitalisation 580.8 m USD, beta 1.48, 52-week range 5.33–10.77 USD. Latest reported quarter (Q2 2026): net income of -10.1 m USD, diluted EPS -0.19 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 75.2
- overbought (≥ 70)
- Bollinger (20, 2)
- 7.06 – 10.37
- above the upper band · %B 1.12 · band width 38.0%
- SMA 50 / 200
- 7.82 / 7.15
- uptrend (price > SMA50 > SMA200)
- MACD (12, 26, 9)
- 0.61 / 0.45
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | +27.9% | −2.0% | +29.9 pp | — |
| 3 months | +61.6% | −2.2% | +63.8 pp | — |
| 6 months | +65.2% | +4.3% | +60.9 pp | — |
| Year to date | +35.3% | +10.6% | +24.7 pp | — |
| 1 year | +60.5% | +10.5% | +50.0 pp | +4.2% |
| 3 years | +324.0% | +73.7% | +250.4 pp | +4.9% |
| 5 years | +131.6% | +61.7% | +69.9 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q2 2026 · 30 Jun 2026
Quarterly statements · USD
| Fiscal year | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Research & development | 5.0 m | 6.5 m | 5.7 m | 5.8 m | 6.4 m | 6.7 m | 8.0 m | 8.2 m |
| Operating income | -6.9 m | -8.4 m | -8.1 m | -8.0 m | -9.0 m | -9.2 m | -10.5 m | -10.5 m |
| Pre-tax income | -6.3 m | -7.9 m | -7.7 m | -7.7 m | -8.6 m | -8.7 m | -10.0 m | -10.1 m |
| Income tax | 7.0 k | 9.0 k | 6.0 k | 6.0 k | 6.0 k | 10.0 k | 7.0 k | 7.0 k |
| Net income | -6.3 m | -7.9 m | -7.7 m | -7.7 m | -8.6 m | -8.7 m | -10.0 m | -10.1 m |
| Diluted EPS | -0.15 | — | -0.18 | -0.18 | -0.17 | — | -0.19 | -0.19 |
| Operating cash flow | -4.5 m ≈ | -6.4 m | -7.1 m | -7.6 m ≈ | -6.6 m ≈ | -7.8 m | -9.1 m | -8.1 m ≈ |
| Capex | 9.0 k ≈ | 7.0 k | 12.0 k | 6.0 k ≈ | 16.0 k ≈ | 6.0 k | 8.0 k | 3.0 k ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 500.0 k | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| Revenue YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| Net income | -5.7 m | -10.6 m | -12.3 m | -13.6 m | -13.7 m | -19.4 m | -24.4 m | -32.8 m |
| Net income YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| Diluted EPS | unavailable | unavailable | unavailable | -0.65 | -0.52 | -0.60 | -0.60 | -0.70 |
| Diluted EPS YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| net % | -1,146.8% | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| Free cash flow | -5.7 m | -9.1 m | -9.2 m | -12.3 m | -11.6 m | -18.8 m | -22.1 m | -29.1 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 15.6 m USD
- Financial debt
- unavailable USD
- Net debt
- unavailable USD
- Equity
- 56.1 m USD
- Total assets
- 61.4 m USD
- Debt / equity
- unavailable
- Current ratio
- 11.81x
- ROE
- -67.7%
- ROA
- -60.8%
- FCF margin
- unavailable
Financial statements (source on every figure)
Revenue and net income (USD)
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Research & development | 8.2 m | 8.8 m | 7.8 m | 13.1 m | 19.1 m | 24.6 m | SEC (XBRL)· 30 Mar 2026verified |
| Operating income | -12.7 m | -13.6 m | -14.0 m | -21.3 m | -26.7 m | -34.4 m | SEC (XBRL)· 30 Mar 2026verified |
| Pre-tax income | -12.3 m | -13.6 m | -13.6 m | -19.3 m | -24.4 m | -32.7 m | SEC (XBRL)· 30 Mar 2026verified |
| Income tax | 27.0 k | 28.0 k | 28.0 k | 43.0 k | 30.0 k | 28.0 k | SEC (XBRL)· 30 Mar 2026verified |
| Net income | -12.3 m | -13.6 m | -13.7 m | -19.4 m | -24.4 m | -32.8 m | SEC (XBRL)· 30 Mar 2026verified |
| Diluted EPS | — | -0.65 | -0.52 | -0.60 | -0.60 | -0.70 | SEC (XBRL)· 30 Mar 2026verified |
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 7.4 m | 4.7 m | 4.7 m | 4.5 m | 3.0 m | 15.6 m | SEC (XBRL)· 30 Mar 2026verified |
| Receivables | 340.0 k | 130.0 k | 82.0 k | 369.0 k | 236.0 k | 258.0 k | SEC (XBRL)· 30 Mar 2026verified |
| Current assets | 27.9 m | 45.4 m | 33.8 m | 53.7 m | 44.6 m | 60.6 m | SEC (XBRL)· 30 Mar 2026verified |
| Property, plant & equipment, net | 74.0 k | 70.0 k | 136.0 k | 131.0 k | 148.0 k | 145.0 k | SEC (XBRL)· 30 Mar 2026verified |
| Total assets | 28.1 m | 45.6 m | 34.4 m | 54.2 m | 46.3 m | 61.4 m | SEC (XBRL)· 30 Mar 2026verified |
| Accounts payable | 1.1 m | 509.0 k | 734.0 k | 926.0 k | 940.0 k | 1.5 m | SEC (XBRL)· 30 Mar 2026verified |
| Current liabilities | 2.0 m | 1.5 m | 2.2 m | 2.8 m | 5.4 m | 5.1 m | SEC (XBRL)· 30 Mar 2026verified |
| Equity | 26.0 m † | 44.0 m † | 31.8 m † | 51.1 m † | 40.7 m † | 56.1 m † | SEC (XBRL)· 30 Mar 2026verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -9.2 m | -12.3 m | -11.5 m | -18.7 m | -22.1 m | -29.1 m | SEC (XBRL)· 30 Mar 2026verified |
| Capex | 47.0 k | 22.0 k | 81.0 k | 24.0 k | 25.0 k | 40.0 k | SEC (XBRL)· 30 Mar 2026verified |
| Free cash flow | -9.2 m ≈ | -12.3 m ≈ | -11.6 m ≈ | -18.8 m ≈ | -22.1 m ≈ | -29.1 m ≈ | SEC (XBRL)· 30 Mar 2026derived |
| Investing cash flow | -16.1 m | -20.5 m | 11.5 m | -18.3 m | 8.6 m | -2.2 m | SEC (XBRL)· 30 Mar 2026verified |
| Financing cash flow | 28.8 m | 30.1 m | -6.0 k | 36.8 m | 12.0 m | 43.9 m | SEC (XBRL)· 30 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 2 of at least 6
- score weight coverage: 12.5% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 580.8 m USD
Key indicators
Coverage and freshness
Score by group
13% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · input data missing
- Peers: EV/EBITDAunavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
no valuation method could be computed
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 2 of at least 6; score weight coverage: 12.5% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | unavailable | unavailable | — |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | unavailable | unavailable | — |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | unavailable | unavailable | — |
| Current ratio · Balance sheet | 6.7x | 100 (on a fixed band) | 33% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | -5.4% | 0 (on a fixed band) | 67% |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet· partial100/100 · 1/3 factors with a value
- Growth· partialunavailable · 0/2 factors with a value
- Quality· partialunavailable · 0/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partial0/100 · 1/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
DiaMedica Therapeutics Inc. (DMAC). Latest full fiscal year: 2018; data up to 2026-06-30.
Figures computed from the financial statements: ROE -114.6%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (indicators available: 2 of at least 6; score weight coverage: 12.5% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Current ratio: 6.7x
What contradicts it
- FCF yield: -5.4%
Not assessed (insufficient data or a ratio without meaning): ROIC, Net margin, FCF conversion, Revenue CAGR 3Y, EPS CAGR 3Y, Net debt / EBITDA, Interest coverage, P/E (TTM), EV/EBITDA, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Pharmaceutical Preparations (SIC 2834) · same industry (4-digit SIC) · compared with 39 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| LLYEli Lilly And Company | 1,325.9 bn | 45.7 | 86.1% | 31.9% | +44.7% | +31% / +138% |
| JNJJohnson & Johnson | 640.8 bn | 40.4 | 20.0% | 16.2% | +6.0% | +29% / +72% |
| ONCBeone Medicines Ltd. | 524.7 bn | 817.5 | 14.7% | 10.7% | +40.2% | +4% / +90% |
| ABBVAbbVie Inc. | 505.5 bn | 49.2 | — | 15.7% | +8.6% | +26% / +101% |
| MRKMerck & Co., Inc. | 356.9 bn | 115.6 | 7.0% | 4.8% | +1.3% | +38% / +41% |
| ABTAbbott Laboratories | 190.6 bn | 30.6 | 12.4% | 13.9% | +5.7% | −15% / +5% |
| PFEPfizer Inc | 171.0 bn | 42.7 | 4.4% | 6.3% | −1.6% | +17% / −2% |
| VRTXVertex Pharmaceuticals Inc | 134.6 bn | 34.2 | 20.8% | 30.7% | +8.9% | +22% / +50% |
| BMYBristol-Myers Squibb Company | 126.1 bn | 13.7 | 44.1% | 18.5% | −0.2% | +25% / +25% |
| TEVATeva Pharmaceutical Industries Limited | 48.9 bn | 97.6 | 6.6% | 3.6% | +4.3% | +56% / +327% |
| ZTSZoetis Inc. | 34.3 bn | 13.7 | 64.4% | 27.5% | +2.3% | −35% / −53% |
| ROIVRoivant Sciences Ltd. | 26.0 bn | — | -6.2% | -3,535.0% | −71.6% | +73% / +277% |
| UTHRUnited Therapeutics Corporation | 25.8 bn | 21.5 | 19.3% | 41.6% | +10.6% | +24% / +151% |
| RPRXRoyalty Pharma plc | 25.8 bn | 37.6 | 8.5% | 32.1% | +5.1% | +66% / +145% |
| INSMInsmed Inc | 22.9 bn | — | -72.5% | -39.9% | +66.7% | −50% / +317% |
| VTRSViatris Inc. | 21.7 bn | — | -23.6% | -23.9% | −3.0% | +77% / +106% |
| ALNYAlnylam Pharmaceuticals, Inc. | 21.4 bn | 8.1 | 126.6% | 52.8% | +65.2% | −65% / −5% |
| TGTXTg Therapeutics, Inc. | 9.4 bn | 22.5 | 100.3% | 55.2% | +87.3% | +85% / +381% |
| BLRXBioLineRx Ltd | 4.9 bn | — | -12.8% | -171.7% | −95.9% | −46% / −97% |
| BHCBausch Health Companies Inc. | 3.1 bn | — | — | -7.6% | +6.7% | +31% / +17% |
| ANABAnaptysbio, Inc. | 1.4 bn | 11.5 | — | 82.4% | +157.0% | +71% / +404% |
| KURAKura Oncology, Inc. | 677.0 m | — | -167.7% | -384.3% | +25.2% | −37% / −21% |
| DMACDiaMedica Therapeutics Inc. | 580.8 m | — | -114.6% | — | unavailable | +61% / +324% |
| PHATPhathom Pharmaceuticals, Inc. | 461.7 m | — | — | -30.2% | +216.9% | −64% / −19% |
| ALTAltimmune, Inc. | 412.4 m | — | -28.9% | -223,804.9% | +105.0% | −60% / −33% |
1- and 3-year price returns: for DMAC from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Scenarios are not available. input data missing
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
DiaMedica Therapeutics develops DM199, a recombinant form of human kallikrein-1, tested for preeclampsia, fetal growth restriction and acute ischemic stroke. The company is still in clinical stage with no approved products, and its net loss of 32.8 million USD in 2025 and cash reserve of 43.5 million USD at June 30, 2026 put funding and study results in focus now 13.
SWOT
Strengths
- DM199 is the first recombinant kallikrein-1 studied clinically in patients, which could offer a more controlled safety profile than extracted forms 1.
- Fast Track designation from the FDA for acute ischemic stroke can facilitate engagement with the regulator 1.
- Interim preeclampsia results show rapid and sustained blood pressure reductions without observed placental transfer 13.
Weaknesses
Opportunities
- If clinical data confirm benefit in preeclampsia, the company could address an unmet need with no approved solutions 1.
- A strategic partnership could support development and commercialization and ease pressure on internal funding 1.
- Expanding studies to Canada and the United Kingdom could accelerate data generation for early-onset preeclampsia 3.
Threats
Risks
- Funding and continuityhigh
The company has no product revenue and expects current resources to last through 2027, which could require new share issues and dilution 13.
- FDA delayshigh
The requested rabbit study could not be completed and alternative models could substantially delay the US timeline 1.
- ReMEDy2 enrollmentmedium
Slow site activation and difficult recruitment could postpone the interim analysis and completion of the study 12.
- Acceptance of foreign datamedium
The FDA could decline the South African study data, which would require additional participants or studies 2.
- Safety and adverse effectsmedium
Side effects of DM199 could limit its commercial profile or delay approval, and the company acknowledges product liability exposure 1.
Investment thesis
What would need to be true (bull case)
- Interim preeclampsia results show significant and sustained blood pressure reductions, and the absence of approved therapies could offer a clear advantage if studies confirm benefit 13.
- Fast Track status and Asian experience with kallikrein-1 could support a regulatory path faster than for an entirely new molecule 1.
- If the ReMEDy2 interim analysis in 2027 is favourable, the company could have stronger grounds for partnerships and financing 3.
What would break the thesis
- The company has no approved products and rising net losses, so additional funding could be needed before decisive results arrive 13.
- FDA nonclinical requirements and slow ReMEDy2 enrollment could significantly delay the timeline 12.
- If the South African data are not accepted or safety effects limit use, the programme's value could fall considerably 12.
What to watch
- Detailed Part 1a preeclampsia results and conference presentation2026
- First patient in the early-onset preeclampsia Phase 2 studyQ4 2026
- ReMEDy2 interim analysisQ1 2027
- Funding plans and length of the cash runway2027
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company, based in Minneapolis, focused on severe ischemic disease 13. Its lead candidate DM199 (rinvecalinase alfa) is the first pharmaceutically active recombinant form of human tissue kallikrein-1 studied clinically in patients and holds FDA Fast Track designation for acute ischemic stroke 1. Longer term, the company plans to develop DM300, a recombinant human ulinastatin, for severe acute pancreatitis 1.
Segments
Preeclampsia and fetal growth restriction
The preeclampsia and fetal growth restriction program is the main near-term priority, centred on an investigator-sponsored Phase 2 study at Tygerberg Hospital in Cape Town 13. Preeclampsia affects up to 8% of pregnancies and roughly 10 million cases occur each year, with no approved therapies in the United States or Europe 1.
Market context
The market DM199 targets includes preeclampsia, which affects up to 8% of pregnancies worldwide, and ischemic stroke, where up to 80% of patients cannot receive thrombolytics or thrombectomy 12. In Asia, kallikrein-1 derived from urine or pig pancreas has been used for decades, supporting a therapeutic market, although the company highlights regulatory differences versus the US and Europe 1.
The final market size for DM199 depends on clinical results, regulatory approvals and payer acceptance, and the company warns its estimates rest on assumptions that could prove inaccurate 1. Assessing the commercial opportunity therefore remains conditional on study progress.
Trends
- Regulatory interest in preeclampsia therapiestailwind
The lack of approved preeclampsia treatments creates an unmet need that could favour faster acceptance of candidates with Fast Track or Breakthrough status, if data are convincing 1.
- Additional FDA requirementsheadwind
The FDA requested extra nonclinical studies before a US Phase 2 start, and antibody responses seen in rabbits complicated their completion, which could delay the timeline 13.
- Difficult enrollment in stroke trialsheadwind
The company reports hospital staffing shortages, strict inclusion criteria and competition for patients, factors that slowed site activation and enrollment in ReMEDy2 12.
- Acceptance of ex-US trial datamixed
Data from the South African study could require added conditions or might not be accepted by the FDA, which could mean extra participants or trials 2.
Competitive position
The company describes its main competitors as Asian products based on urine-derived or porcine pancreas-derived kallikrein-1, sold in Japan, China and South Korea, where about 20 companies market the porcine form 1. In the US and Europe, the company states no comparable products are currently approved 1.
The company warns that in preeclampsia and stroke, better-resourced partners or rivals could accelerate alternative therapies, and DM199 could face competition sooner than expected 1.
- Tech-pool BioPharma / Shanghai Pharmaceuticals
Sells urine-derived kallikrein-1 (Kailikang) in China for ischemic stroke, according to the company 1.
- Porcine pancreas-derived kallikrein-1 producers
Around 20 companies sell this form in Japan, China and South Korea for hypertension and vascular disease 1.
- Vasodilators with other mechanisms
The company cites nitric oxide donors, prostacyclin analogues and endothelium-derived factor stimulators as preclinical alternatives without approvals 1.
- Standard antihypertensives used in pregnancy
The company notes common hypertension drugs cross the placental barrier or are contraindicated in pregnancy, leaving room for new therapies 1.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
No news in our archive over the last 180 days.
SEC filings
- Quarterly report10 Aug 2026
- Current report10 Aug 2026Results of operations · Financial statements and exhibits
- Current report21 May 2026Shareholder vote
- Quarterly report06 May 2026
- Current report06 May 2026Results of operations · Financial statements and exhibits
- Proxy statement01 Apr 2026
- Current report31 Mar 2026Results of operations · Financial statements and exhibits
- Annual report30 Mar 2026
- Current report05 Jan 2026Other events
- Current report18 Dec 2025Regulation FD disclosure · Other events · Financial statements and exhibits
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / DiaMedica Therapeutics Inc. · 30 Mar 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / DiaMedica Therapeutics Inc. · 10 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / DiaMedica Therapeutics Inc. · 10 Aug 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.